BioNTech SE (BNTX) Misses Q4 EPS by 46c, Misses on Revenue; Offers FY24 Revenue Guidance

BioNTech SE (NASDAQ: BNTX) reported Q4 EPS of EUR1.90, EUR0.46 worse than the analyst estimate of EUR2.36. Revenue for the quarter came in at EUR1.48 billion versus the consensus estimate of EUR2.02 billion.

For full year 2024 the company sees revenue of €2.5 billion to €3.1 billion vs analyst estimate of €3.44 billion.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy
• AbbVie agrees to acquire Apogee Therapeutics for $10.9 billion